Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
复制标题
同时靶向 CD45 显着增加抗 CD33 免疫偶联物吉妥珠单抗奥佐米星 (gemtuzumab ozogamicin) 针对急性髓系白血病 (AML) 细胞的细胞毒性，并提高携带人类 AML 异种移植物的小鼠的存活率。
DOI：
10.1182/blood-2008-01-133785
复制
发表时间：
2008
期刊：
影响因子：
20.3
通讯作者：
Pagel,JohnM
中科院分区：
文献类型：
--
作者：
Walter,RolandB;Boyle,KelliM;Appelbaum,FrederickR;Bernstein,IrwinD;Pagel,JohnM
